• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: small molecule that selectively and irreversibly inhibits the KRAS p.G12C mutant protein
Date Designated: 07/22/2025
Orphan Designation: treatment of colorectal cancer (CRC) harboring KRAS p.G12C mutant protein
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
D3 Bio (Wuxi) Co., Ltd
1101, Tower 1, No.6, Lane 38, Yuanshan Road
Pudong
Shanghai 200120
China

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-